Carmelo Mendiola, MD
Internal Medicine · Fort Payne, ALNPI 1023063922
Payments from drug & device makers
Across 569 payments — averaging $11.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$2K
- Novo Nordisk$920
- AstraZeneca$582
- GSK$566
- Merck$450
- Amgen$449
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,42595%
- Education$3325%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 261 | $1,783 |
| Novo Nordisk | 71 | $920 |
| AstraZeneca | 36 | $582 |
| GSK | 31 | $566 |
| Merck | 24 | $450 |
| Amgen | 28 | $449 |
| Lilly USA, LLC | 27 | $432 |
| Novartis | 11 | $209 |
| Bayer | 11 | $187 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| Sanofi-aventis U.S. LLC | 8 | $111 |
| AbbVie | 7 | $106 |
| Amarin Pharma, Inc. | 7 | $102 |
| Abbott | 4 | $75 |
| Akebia Therapeutics Inc | 3 | $65 |
| Pfizer | 3 | $59 |
| Exact Sciences | 3 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Calliditas Therapeutics US Inc. | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Eisai Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $24 |
| Organogenesis Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Medtronic | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$6,757 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 231 | $394,235 |
| EliquisApixaban | 409 | $333,560 |
| OzempicSemaglutide | 235 | $244,328 |
| MounjaroTirzepatide | 194 | $224,443 |
| JardianceEmpagliflozin | 108 | $106,950 |
| TrulicityDulaglutide | 86 | $83,963 |
| FarxigaDapagliflozin Propanediol | 89 | $69,480 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $65,798 |
| JanuviaSitagliptin Phosphate | 62 | $65,136 |
| LinzessLinaclotide | 88 | $53,426 |
| Repatha SureclickEvolocumab | 59 | $41,903 |
| XareltoRivaroxaban | 41 | $40,453 |
| EntrestoSacubitril/Valsartan | 39 | $37,647 |
| RybelsusSemaglutide | 18 | $30,382 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $26,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $1,783 | $394,235231 claims |
| PfizerEliquis | $59 | $333,560409 claims |
| Lilly USA, LLCMounjaro, Trulicity | $432 | $308,407280 claims |
| Novo NordiskOzempic, Rybelsus | $920 | $274,709253 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $13 | $128,897143 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $582 | $100,103160 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $566 | $92,056148 claims |
| MerckJanuvia, Janumet Xr | $450 | $81,56574 claims |
| AbbVieLinzess | $106 | $53,42688 claims |
| NovartisEntresto | $209 | $37,64739 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $11 | $12,65926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Fort Payne
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.